Dr Shanthi Sabarimurugan is a Post-Doctoral researcher in Genesis Care, Australia and holds an academic position (Microbiology/Immunology) in the University of Western Australia. She is a University Rank holder during her Postgraduate/Undergraduate in Microbiology discipline. She obtained her PhD from the University of Madras, India in 2016. She defended her thesis on identifying and evaluating the efficacy of novel compounds against all serotypes of Dengue virus, where molecules are under final investigation in Indian Patent Rights. She has worked in various virology projects funded by Government of India on evaluation the antiviral molecules on Dengue virus, Chikungunya virus, Shingles and Herpes Simplex Virus. Her current research interest focus on the development of antivirals, efficacy of Radioligand therapy on cancer patients. Her meta-analysis evaluation on miRNA prognostic significance on multiple carcinomas such as Nasopharyngeal carcinoma, melanoma, colorectal cancer & T-Cell acute lymphoblastic leukemia has well acknowledged.